



Ventripoint Receives Additional Funding to Develop Next Generation of the VMS+, Whole-Heart Analysis System

Toronto, Ontario – The Newswire – December 6, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that Ventripoint has received additional advisory services and up to \$107,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). This new funding is in addition to the up to \$120,000 that has already been approved.

“Ventripoint’s mission is to improve cardiac diagnosis for everyone, worldwide and especially for children, so it is wonderful to have the support of the Government of Canada through NRC IRAP as we push the limits of our technology to even better performance,” stated Dr. George Adams, CEO of Ventripoint.

It is important for medical device companies to always be advancing their products to keep ahead of the competition and this support will be used to develop the next generation of the VMS+ products. The Company has been working with an international committee of cardiologists to define new measurements of heart function to improve diagnose and patient care. The combined funding of up to \$227,000 will provide Ventripoint with the resources and advisory services to further enhance the VMS+ system to revolutionize the way heart analysis is performed.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams
gadams@ventripoint.com
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.